2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP01.08

EP01.08 - Liwei Song

Pdf Summary

This study, conducted by a team at the Beijing Chest Hospital, investigates the effectiveness of neoadjuvant therapy for patients with limited-stage small cell lung cancer (LS-SCLC). Given that the primary treatment for LS-SCLC typically involves platinum-based chemotherapy combined with radiation therapy, the study aims to evaluate alternative treatments, particularly focusing on pathological responses to neoadjuvant therapy.<br /><br />Between March 2018 and February 2024, the team retrospectively analyzed data from 23 patients who received neoadjuvant therapy. The patients were divided into two groups, those achieving a pathological complete response (pCR) and those who did not (non-pCR). The analysis aimed to identify clinical factors that correlated with achieving pCR and was carried out using SPSS 20.0 software.<br /><br />Results revealed that patients who achieved pCR had undergone a neoadjuvant treatment regimen combining immunotherapy and chemotherapy. In contrast, 50% of patients in the non-pCR group received only chemotherapy. The difference in response between these two treatment regimens was statistically significant (P=0.019). Furthermore, preoperative imaging indicated that the pCR group experienced greater tumor reduction, averaging 80% compared to 67% in the non-pCR group (P=0.022). There were no significant differences regarding age, gender, median therapy cycles, tumor markers (NSE, ProGRP), surgical approach, or other indicators between the two groups.<br /><br />The conclusion drawn from the study is that a combination of chemotherapy and immunotherapy as neoadjuvant treatment provides a higher pathological complete response rate compared to chemotherapy alone in patients with LS-SCLC. This suggests that integrating immunotherapy into the treatment regimen could offer a promising new strategy for managing this stage of lung cancer.

Keywords

neoadjuvant therapy

small cell lung cancer

LS-SCLC

pathological complete response

immunotherapy

chemotherapy

tumor reduction

Beijing Chest Hospital

retrospective analysis

treatment regimen